Overview

Topical rVA576 for Treatment of Atopic Keratoconjunctivitis

Status:
Terminated
Trial end date:
2020-12-15
Target enrollment:
Participant gender:
Summary
Topical rVA576 for treatment of atopic keratoconjunctivitis: a randomised placebo-controlled double masked parallel trial (TRACKER)
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AKARI Therapeutics